Erratum. Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A). Diabetes Care 2016;39:139–148
- Tomoya Mita,
- Naoto Katakami,
- Hidenori Yoshii,
- Tomio Onuma,
- Hideaki Kaneto,
- Takeshi Osonoi,
- Toshihiko Shiraiwa,
- Keisuke Kosugi,
- Yutaka Umayahara,
- Tsunehiko Yamamoto,
- Hiroki Yokoyama,
- Nobuichi Kuribayashi,
- Hideaki Jinnouchi,
- Masahiko Gosho,
- Iichiro Shimomura,
- Hirotaka Watada and
- , on behalf of the Collaborators on the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A) Trial
In the Research Design and Methods section of the above-mentioned article, the measurement of carotid intima-media thickness (IMT) was described as follows: “The software system averaged 60 points of IMT values in the segment 2 cm proximal to the dilation of the carotid bulb (mean-IMT-CCA).” The sentence should read: “The software system averaged ∼200 points of IMT values in the segment 2 cm proximal to the dilation of the carotid bulb (mean-IMT-CCA).”
The authors believe that this correction will not affect the results obtained in the study, and they regret the error.
The online version of the article has been corrected.
- © 2017 by the American Diabetes Association.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.
In this Issue
